Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29203043 | 0.83 | CYP11B2 (0.41) | KDM4EALDH1A1KMT2AGAAPDK1 | |
| SCHEMBL30882906 | 0.83 | CYP11B2 (0.41) | KDM4EALDH1A1KMT2AGAAPDK1 | |
| SCHEMBL7898049 | 0.83 | CYP2C19 (0.47) | KDM4EALDH1A1KMT2AGAACYP2C19 | |
| Hydrochloric Acid SCHEMBL21192421 | 0.77 | ALDH1A1 (0.45) | KDM4EALDH1A1KMT2AGAAPDK1 | |
| SCHEMBL16720987 | 0.77 | ALDH1A1 (0.47) | KDM4EALDH1A1KMT2AGAAPDK1 | |
| SCHEMBL28201234 | 0.77 | ALDH1A1 (0.47) | KDM4EALDH1A1KMT2AGAAPDK1 | |
| SCHEMBL25025992 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1KMT2AGAAPDK1 | |
| SCHEMBL871448 | 0.75 | ALDH1A1 (0.50) | KDM4EALDH1A1KMT2AGAAPDK1 | |
| SCHEMBL21831956 | 0.75 | KDM4E (0.45) | KDM4EALDH1A1KMT2AGAAPDK1 | |
| SCHEMBL30882953 | 0.75 | KMT2A (0.45) | KDM4EALDH1A1KMT2AGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465737-B2 | Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20070225300-A1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-09-27 | — | — | US | disclosed |
| US-7232827-B2 | Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2007-06-19 | — | — | US | disclosed |
| EP-1480983-B1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYDIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2005-11-09 | — | — | EP | disclosed |
| US-20050222172-A1 | Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives | SANOFI (FR) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225300-A1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | CDK5, CDK5R1, PSEN2 | KDM4E 2042/4885ALDH1A1 1879/4885KMT2A 1815/4885 |
| US-20050222172-A1 | Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives | GSK3A, GSK3B, CDK5 | KDM4E 2806/4885ALDH1A1 1088/4885KMT2A 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.